Esketamine spray for treating depression 'not cost-effective' A nasal esketamine spray for hard-to-treat depression has been rejected for use on the NHS for a second time because of uncertainty over cost.
Despite a need for new treatments for adults, it is also not clear how well the drug works long term, the healthcare watchdog NICE said.
Esketamine is a form of ketamine that targets a chemical linked with learning and memory. BBC News
No comments:
Post a Comment